Literature DB >> 23907620

FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease.

Haifeng Ni1, Junfeng Chen, Mingming Pan, Minghui Zhang, Jiandong Zhang, Pingsheng Chen, Bicheng Liu.   

Abstract

Recent studies have shown that chronic endothelial dysfunction can impair multiple aspects of renal physiology and, in turn, contribute to renal fibrosis. Sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. The aim of our study was to investigate the effect of FTY720, an S1P analog, on the progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease. Thirty male Sprague-Dawley rats were used in this study. Seven days after surgery, we placed the animals into three groups: sham surgery; 5/6 nephrectomized (Nx) rats; and 5/6Nx + FTY720 (1 mg/kg/day). All of the animals were sacrificed 12 weeks after surgery. We obtained and analyzed blood and kidney tissue samples from all of the groups. Glomerular capillary density and peritubular capillary (PTC) density were determined by CD31 immunostaining. The expression of transforming growth factor beta 1 (TGF-β1), collagen IV, fibronectin, endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) were analyzed by immunohistochemistry, reverse transcription-polymerase chain reaction and western blotting. The 5/6Nx group exhibited increased blood urea nitrogen and serum creatinine, visible renal histological changes, pro-fibrotic molecule (TGF-β1) and production of extracellular matrix proteins such as collagen IV and fibronectin and decreased glomerular and PTC density, compared to the sham controls (P < 0.01). We observed that treatment with FTY720 reduced these abnormalities. Furthermore, the level of NO, the expression levels of eNOS and VEGF were downregulated in the kidney tissue in 5/6Nx rats, FTY720 treatment significantly attenuated this decrease. FTY720 prevents the progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907620     DOI: 10.1007/s10735-013-9521-8

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  44 in total

Review 1.  Role of the microvascular endothelium in progressive renal disease.

Authors:  Duk-Hee Kang; John Kanellis; Christian Hugo; Luan Truong; Sharon Anderson; Dontscho Kerjaschki; George F Schreiner; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2002-03       Impact factor: 10.121

Review 2.  Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease.

Authors:  Minoru Satoh
Journal:  Clin Exp Nephrol       Date:  2012-06-06       Impact factor: 2.801

3.  The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.

Authors:  Cuiyan Xin; Shuyu Ren; Wolfgang Eberhardt; Josef Pfeilschifter; Andrea Huwiler
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Dilator and constrictor response of renal vasculature during acute renal hypotension in anesthetized goats. Role of nitric oxide.

Authors:  Godofredo Diéguez; Angel Luis García-Villalón
Journal:  Vascul Pharmacol       Date:  2011-05-06       Impact factor: 5.773

5.  Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis.

Authors:  A Hara; T Wada; K Furuichi; N Sakai; H Kawachi; F Shimizu; M Shibuya; K Matsushima; H Yokoyama; K Egashira; S Kaneko
Journal:  Kidney Int       Date:  2006-06       Impact factor: 10.612

Review 6.  Nitric oxide synthase derangements and hypertension in kidney disease.

Authors:  Chris Baylis
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

7.  Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.

Authors:  Matthias Schaier; Stefanie Vorwalder; Claudia Sommerer; Ralf Dikow; Friederike Hug; Marie-Luise Gross; Rüdiger Waldherr; Martin Zeier
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-17

8.  Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse.

Authors:  Takahiro Nakayama; Waichi Sato; Tomoki Kosugi; Li Zhang; Martha Campbell-Thompson; Ashio Yoshimura; Byron P Croker; Richard J Johnson; Takahiko Nakagawa
Journal:  Am J Physiol Renal Physiol       Date:  2008-11-26

Review 9.  Lysophospholipid receptors: signaling and biology.

Authors:  Isao Ishii; Nobuyuki Fukushima; Xiaoqin Ye; Jerold Chun
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

10.  Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy.

Authors:  Lin Ji; Satohiro Masuda; Hideyuki Saito; Ken-ichi Inui
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

View more
  16 in total

1.  FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells.

Authors:  Yaxian Kong; Hong Wang; Shuling Wang; Na Tang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

2.  Sphingolipids and Redox Signaling in Renal Regulation and Chronic Kidney Diseases.

Authors:  Owais M Bhat; Xinxu Yuan; Guangbi Li; RaMi Lee; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2018-01-09       Impact factor: 8.401

3.  Localization and expression profile of Group I and II Activators of G-protein Signaling in the kidney.

Authors:  Marek Lenarczyk; Jeffrey D Pressly; Joanna Arnett; Kevin R Regner; Frank Park
Journal:  J Mol Histol       Date:  2014-12-23       Impact factor: 2.611

4.  Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-κB and MAPK signal pathways.

Authors:  Wei Wang; Pang-hu Zhou; Chang-geng Xu; Xiang-jun Zhou; Wei Hu; Jie Zhang
Journal:  J Mol Histol       Date:  2015-05-17       Impact factor: 2.611

Review 5.  Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease.

Authors:  Ryan J Adam; Adaysha C Williams; Alison J Kriegel
Journal:  Am J Physiol Renal Physiol       Date:  2022-04-04

Review 6.  Endothelial Dysfunction in Renal Interstitial Fibrosis.

Authors:  Heather M Perry; Mark D Okusa
Journal:  Nephron       Date:  2016-08-30       Impact factor: 2.847

7.  Sphingosine-1-phosphate and its mimetic FTY720 do not protect against radiation-induced ovarian fibrosis in the nonhuman primate†.

Authors:  Farners Amargant; Sharrón L Manuel; Megan J Larmore; Brian W Johnson; Maralee Lawson; Michele T Pritchard; Mary B Zelinski; Francesca E Duncan
Journal:  Biol Reprod       Date:  2021-05-07       Impact factor: 4.285

8.  Targeting tubulointerstitial remodeling in proteinuric nephropathy in rats.

Authors:  Saleh Yazdani; Ryanne S Hijmans; Fariba Poosti; Wendy Dam; Gerjan Navis; Harry van Goor; Jacob van den Born
Journal:  Dis Model Mech       Date:  2015-05-14       Impact factor: 5.758

9.  Ozone oxidative preconditioning inhibits renal fibrosis induced by ischemia and reperfusion injury in rats.

Authors:  Lei Wang; Hui Chen; Xiu-Heng Liu; Zhi-Yuan Chen; Xiao-Dong Weng; Tao Qiu; Lin Liu; Heng-Cheng Zhu
Journal:  Exp Ther Med       Date:  2014-10-06       Impact factor: 2.447

10.  Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.

Authors:  Petr Kujal; Vera Čertíková Chábová; Petra Škaroupková; Zuzana Husková; Zdena Vernerová; Herbert J Kramer; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Kento Kitada; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Ludek Červenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-03       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.